Kate Dawson from Biogen: New Research Shows Long Term Benefits of Tecfidera

APRIL 18, 2016
Adam Hochron

As more research is collected about Tecfidera's usage since clinical trials and approval there continue to be signs that it can be a good treatment option for patients with multiple sclerosis, especially in the earliest stages.

At the 68th Annual Meeting of the American Academy of Neurology Kate Dawson, MD, from Biogen discussed some of the latest results from one of the newest approved treatments for the condition. While being relatively new Dawson said the results show the medication to be a viable option which can help this patient population.  

Copyright© MD Magazine 2006-2018 Intellisphere, LLC. All Rights Reserved.